L3VLUP
ProSign in

BHVN · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

BHVNLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • BHVN
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterBHVNLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 2021none listed holders, n.a.31 holders, $29.9bn
Q4 2021none listed holders, n.a.31 holders, $34.7bn
Q1 2022none listed holders, n.a.24 holders, $35.3bn
Q2 2022none listed holders, n.a.33 holders, $42.7bn
Q3 20223 holders, $180m31 holders, $43.4bn
Q4 20228 holders, $159m31 holders, $46.6bn
Q1 20238 holders, $178m33 holders, $44.3bn
Q2 202310 holders, $272m37 holders, $59.6bn
Q3 20237 holders, $293m44 holders, $67.6bn
Q4 20239 holders, $638m45 holders, $73.6bn
Q1 20248 holders, $741m41 holders, $95.3bn
Q2 20246 holders, $384m43 holders, $110bn
Q3 20249 holders, $861m45 holders, $107bn
Q4 20246 holders, $533m46 holders, $93.9bn
Q1 20255 holders, $344m42 holders, $98.4bn
Q2 20254 holders, $120m43 holders, $93.2bn
Q3 20253 holders, $128m39 holders, $86.7bn
Q4 20255 holders, $62m41 holders, $123bn
Q1 20264 holders, $173m39 holders, $106bn
Q2 20265 holders, $273m44 holders, $132bn
BHVN

Biohaven LTD

Holders
9
Reported value
$861m
Buyers
5
Sellers
3

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
45
Reported value
$107bn
Buyers
24
Sellers
22

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 47 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only BHVN (2)

Farallon Capital Management LLC, Point72 Asset Management LP

Only LLY (38)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, and 13 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →